Patients with axial spondyloarthritis (axSpA) are at increased risk of mental disorders, suggests a recent study. High disease activity, combined with a certain sociodemographic profile, is a good indicator of such risk.
Using diclofenac in combination with TPC (thiamine, pyridoxine and cyanocobalamin) offers superior analgesic effect than diclofenac monotherapy in the management of acute lower back pain, according to a systematic review and meta-analysis.
Gout entails an increased risk of advanced chronic kidney disease (CKD), and the risk is strongest for the outcome of end-stage kidney disease (ESKD) but extended to other surrogate measures of CKD progression, a study has found.
Partial knee replacement surgery provides similar clinical outcomes as total knee replacement in patients with late-stage osteoarthritis (OA), although the former proves more cost-effective according to the results of the TOPKAT* trial.
The previous use of multiple disease-modifying antirheumatic drugs (DMARDs) and disease duration appear to affect treatment outcomes in rheumatoid arthritis patients initiating adalimumab therapy, according to a posthoc analysis of two randomized controlled trials.
Ethnic variations are present in some systemic sclerosis (SSc) disease manifestations, and although this does not lead to significant differences in short-term survival, it may influence long-term survival, suggests a recent study.
Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).